LAVA Historical Income Statement

LVTX Stock

USD 1.60 0.05 3.23%

Historical analysis of LAVA Therapeutics income statement accounts such as Interest Expense of 300.7 K can show how well LAVA Therapeutics NV performed in making a profits. Evaluating LAVA Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of LAVA Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining LAVA Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether LAVA Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LAVA Therapeutics NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About LAVA Income Statement Analysis

LAVA Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to LAVA Therapeutics shareholders. The income statement also shows LAVA investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

LAVA Therapeutics Income Statement Chart

At this time, LAVA Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 1.3 M in 2024, whereas Tax Provision is likely to drop slightly above 158.4 K in 2024.

Selling General Administrative Research Development Total Operating Expenses Reconciled Depreciation

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from LAVA Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into LAVA Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LAVA Therapeutics NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2021	2022	2023	2024 (projected)
Interest Expense	625K	82K	232K	300.7K
Depreciation And Amortization	558K	504K	1.3M	1.3M

Interest Expense Depreciation And Amortization

LAVA Therapeutics income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Interest Income
Net Interest Income		0.94	0.14	0.53	0.54	-0.66	-0.64	-0.65	0.49	-0.64	0.5	0.77	-0.64	0.61	-0.64	0.68	0.45	-0.5	0.94
Depreciation And Amortization	0.94		0.41	0.74	0.75	-0.86	-0.85	-0.86	0.71	-0.85	0.72	0.86	-0.85	0.6	-0.85	0.79	0.63	-0.73	0.91
Interest Expense	0.14	0.41		0.57	0.63	-0.69	-0.72	-0.72	0.63	-0.73	0.54	0.41	-0.73	-0.19	-0.73	0.26	0.41	-0.61	0.24
Selling General Administrative	0.53	0.74	0.57		1.0	-0.95	-0.94	-0.94	0.99	-0.94	0.98	0.89	-0.94	0.67	-0.94	0.92	0.96	-0.99	0.57
Other Operating Expenses	0.54	0.75	0.63	1.0		-0.96	-0.96	-0.95	1.0	-0.96	0.97	0.89	-0.96	0.62	-0.96	0.89	0.94	-0.98	0.58
Operating Income	-0.66	-0.86	-0.69	-0.95	-0.96		1.0	1.0	-0.95	1.0	-0.94	-0.87	1.0	-0.56	1.0	-0.85	-0.87	0.96	-0.67
Net Income From Continuing Ops	-0.64	-0.85	-0.72	-0.94	-0.96	1.0		1.0	-0.94	1.0	-0.93	-0.85	1.0	-0.52	1.0	-0.83	-0.85	0.95	-0.66
Ebit	-0.65	-0.86	-0.72	-0.94	-0.95	1.0	1.0		-0.94	1.0	-0.92	-0.86	1.0	-0.51	1.0	-0.83	-0.84	0.95	-0.67
Research Development	0.49	0.71	0.63	0.99	1.0	-0.95	-0.94	-0.94		-0.94	0.97	0.86	-0.94	0.62	-0.94	0.87	0.95	-0.99	0.52
Ebitda	-0.64	-0.85	-0.73	-0.94	-0.96	1.0	1.0	1.0	-0.94		-0.93	-0.85	1.0	-0.51	1.0	-0.82	-0.84	0.95	-0.66
Total Operating Expenses	0.5	0.72	0.54	0.98	0.97	-0.94	-0.93	-0.92	0.97	-0.93		0.84	-0.92	0.67	-0.92	0.92	0.95	-0.99	0.54
Reconciled Depreciation	0.77	0.86	0.41	0.89	0.89	-0.87	-0.85	-0.86	0.86	-0.85	0.84		-0.85	0.66	-0.85	0.93	0.78	-0.82	0.85
Income Before Tax	-0.64	-0.85	-0.73	-0.94	-0.96	1.0	1.0	1.0	-0.94	1.0	-0.92	-0.85		-0.5	1.0	-0.82	-0.84	0.95	-0.66
Total Other Income Expense Net	0.61	0.6	-0.19	0.67	0.62	-0.56	-0.52	-0.51	0.62	-0.51	0.67	0.66	-0.5		-0.51	0.83	0.79	-0.64	0.49
Net Income	-0.64	-0.85	-0.73	-0.94	-0.96	1.0	1.0	1.0	-0.94	1.0	-0.92	-0.85	1.0	-0.51		-0.82	-0.84	0.95	-0.66
Income Tax Expense	0.68	0.79	0.26	0.92	0.89	-0.85	-0.83	-0.83	0.87	-0.82	0.92	0.93	-0.82	0.83	-0.82		0.89	-0.88	0.72
Gross Profit	0.45	0.63	0.41	0.96	0.94	-0.87	-0.85	-0.84	0.95	-0.84	0.95	0.78	-0.84	0.79	-0.84	0.89		-0.96	0.41
Cost Of Revenue	-0.5	-0.73	-0.61	-0.99	-0.98	0.96	0.95	0.95	-0.99	0.95	-0.99	-0.82	0.95	-0.64	0.95	-0.88	-0.96		-0.51
Interest Income	0.94	0.91	0.24	0.57	0.58	-0.67	-0.66	-0.67	0.52	-0.66	0.54	0.85	-0.66	0.49	-0.66	0.72	0.41	-0.51

Click cells to compare fundamentals

LAVA Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for LAVA Stock Analysis

When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

LAVA Historical Income Statement

About LAVA Income Statement Analysis

LAVA Therapeutics Income Statement Chart

Total Operating Expenses

LAVA Therapeutics income statement Correlations

LAVA Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for LAVA Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Net Interest Income
Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Ebitda
Total Operating Expenses	Reconciled Depreciation
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Gross Profit
Cost Of Revenue	Interest Income

Other Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income

Cost Of Revenue	- 0.99	Total Operating Expenses
Cost Of Revenue	- 0.99	Research Development
Cost Of Revenue	- 0.99	Selling General Administrative
Cost Of Revenue	- 0.98	Other Operating Expenses
Cost Of Revenue	- 0.96	Gross Profit
Net Income	- 0.96	Other Operating Expenses